EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance

Soo-Bong Park, Myeong-Yeon Kim, Sun-Shin Cha

Journal of Microbiology · 2026

DOI: 10.71150/jm.2510019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Microbiology, 2026. Verfasst von Soo-Bong Park und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactamases, Anti-Bacterial Agents, Bacteria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Institute of Ocean Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β-Lactam antibiotics marked the beginning of an era of effective and safe treatment for bacterial infections and remain the most widely prescribed antibacterial agents today. However, the emergence of antibiotic-resistant bacteria threatens a return to the pre-antibiotic era. In particular, bacterial expression of β-lactamases inactivating β-lactam antibiotics presents a challenge in antimicrobial therapy. While inhibitors against β-lactamases have been developed to protect the therapeutic efficacy of β-lactam antibiotics, the clinical use of β-lactamase inhibitors is constrained due to their limited inhibition spectrum and the emergence of inhibitor-resistant β-lactamase variants. As an effort to tackle this issue, here we reviewed the structural and mechanistic features of β-lactamases and their FDA-approved inhibitors. Moreover, mutations in clinically isolated β-lactamases that confer resistance against their inhibitors are compiled. The comprehensive overview offered in this review aims to support and stimulate the design of next-generation β-lactamase inhibitors for combating β-lactamase-mediated antibiotic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsBacteriaHumansbeta Lactam Antibioticsbeta-Lactam ResistanceBacterial InfectionsMutationDrug Resistance, Bacterial

Stichwörter der Autor:innen

BLI with novel scaffoldclinically isolated β-lactamase resistance against BLIinhibition mechanisminhibition spectrumpan-β-lactamase inhibitorstructure and function of β-lactamase inhibitor (BLI)

Substanzen

beta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial Agentsbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea.
  • Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul 03760, Republic of Korea.
  • R&D Division, TODD PHARM CO. LTD., Seoul 03760, Republic of Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korea Institute of Ocean Science and Technology

Zitieren

APA

Park, S. B., Kim, M. Y., & Cha, S. S. (2026). Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. Journal of Microbiology. https://doi.org/10.71150/jm.2510019

Vancouver

Park SB, Kim MY, Cha SS. Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. Journal of Microbiology. 2026. doi:10.71150/jm.2510019

BibTeX
@article{Park2026,
  author = {Park, Soo-Bong and Kim, Myeong-Yeon and Cha, Sun-Shin},
  title = {Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance},
  journal = {Journal of Microbiology},
  year = {2026},
  doi = {10.71150/jm.2510019}
}
Kostenlos starten →